<--- Back to Details
First PageDocument Content
Drugs / Pharmaceuticals policy / Clinical pharmacology / Prescription medication / Pharmaceutical drug / Medical prescription / Pharmacy / Substance abuse / Prescription costs / Pharmacology / Pharmaceutical sciences / Medicine
Date: 2013-06-12 10:24:34
Drugs
Pharmaceuticals policy
Clinical pharmacology
Prescription medication
Pharmaceutical drug
Medical prescription
Pharmacy
Substance abuse
Prescription costs
Pharmacology
Pharmaceutical sciences
Medicine

Drug-Induced Deaths July 2012 Issue Brief

Add to Reading List

Source URL: dhmh.maryland.gov

Download Document from Source Website

File Size: 146,34 KB

Share Document on Facebook

Similar Documents

Seminars on Drug Discovery & Development Wednesdays 17::00, Lecture Hall 1, Pharmazentrum, Klingelbergstrasse 50, Basel Feb 24, 16 Prof. Dr. G. Klebe, Institute of Pharmaceutical Chemistry, Philipps-University Mar

DocID: 1vnYL - View Document

Send Orders of Reprints at 614 Current Pharmaceutical Design, 2013, 19, Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets

DocID: 1v1vA - View Document

eclipse | RBM data sheet Risk Based Monitoring (RBM) Drug costs are soaring. The pharmaceutical, biotech and CRO industries are more competitive than ever before. Companies like yours are looking for ways to reduce expe

DocID: 1uZyk - View Document

2nd APV Conference on “Highly Potent Drug Products in the Pharmaceutical Industry” 26 to 27 September 2018 Mannheim, Germany

DocID: 1utU5 - View Document

AIDS Treatment Activists Coalition (ATAC) Pharmaceutical Company HIV/AIDS Report Card Issued by the ATAC Drug Development Committee September 10, 2009

DocID: 1u8Vg - View Document